Single dose of psilocybin improves depressive symptoms in Phase 2 study

A single 25-mg dose of psilocybin administered with psychological support led to significant and sustained improvement in depressive symptoms compared with placebo in a Phase 2 study of patients with major depressive disorder. A higher number of adverse events occurred in the psilocybin group, but no serious treatment-emergent adverse events were reported. Study results were published online Aug. 31, 2023, in JAMA.